Clinical trial DeLLphi-306
A phase 3, randomized, double-blind, placebo-controlled, multicenter study of Tarlatamab therapy in subjects with limited-stage small-cell lung cancer (LS-SCLC) who have not pregressed following concurrent chemoradiation therapy (DeLLphi-306)
| Cancers | |
|---|---|
| Organ | Lung |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Amgen |
| EudraCT Identifier | 2023-506235-15-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT06117774 |
| Last update |